All lobbying filings

CGCN GROUP, LLC

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Biopharmaceutical Company

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 4

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Access to innovative non-opioid medicines.

Medicare/Medicaid

Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.

Bills named in this filing 2

H.R. 1227
Alternatives to PAIN Act
S. 475
Alternatives to PAIN Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.